Calcineurin inhibition rescues early synaptic plasticity deficits in a mouse model of Alzheimer's disease

Neuromolecular Med. 2013 Sep;15(3):541-8. doi: 10.1007/s12017-013-8241-2. Epub 2013 Jul 3.

Abstract

Functional and ultrastructural investigations support the concept that altered brain connectivity, exhausted neural plasticity, and synaptic loss are the strongest correlates of cognitive decline in age-related neurodegenerative dementia of Alzheimer's type. We have previously demonstrated that in transgenic mice, expressing amyloid-β precursor protein-Swedish mutation active caspase-3 accumulates in hippocampal postsynaptic compartments leading to altered postsynaptic density (PSD) composition, increased long-term depression (LTD), and dendritic spine loss. Furthermore, we found strong evidence that dendritic spine alteration is mediated by calcineurin activation, a calcium-dependent phosphatase involved in synapse signaling. In the present work, we analyzed the molecular mechanism linking alteration of synaptic plasticity to the increase of calcineurin activity. We found that acute treatment of young and plaque-free transgenic mice with the calcineurin inhibitor FK506 leads to a complete rescue of LTD and PSD composition. Our findings are in agreement with other results reporting that calcineurin inhibition improves memory function and restores dendritic spine density, confirming that calcineurin inhibition may be explored as a neuroprotective treatment to stop or slowdown synaptic alterations in Alzheimer's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / physiopathology
  • Alzheimer Disease / prevention & control*
  • Animals
  • CA1 Region, Hippocampal / drug effects*
  • CA1 Region, Hippocampal / metabolism
  • CA1 Region, Hippocampal / physiopathology
  • Calcineurin Inhibitors*
  • Caspase 3 / metabolism
  • Dendrites / drug effects
  • Dendrites / ultrastructure
  • Disease Models, Animal
  • Disks Large Homolog 4 Protein
  • Drug Evaluation, Preclinical
  • Excitatory Postsynaptic Potentials / drug effects
  • Guanylate Kinases / biosynthesis
  • Guanylate Kinases / genetics
  • Long-Term Synaptic Depression / drug effects*
  • Male
  • Membrane Proteins / biosynthesis
  • Membrane Proteins / genetics
  • Methoxyhydroxyphenylglycol / analogs & derivatives
  • Methoxyhydroxyphenylglycol / pharmacology
  • Mice
  • Mice, Transgenic
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Phosphorylation / drug effects
  • Phosphoserine / metabolism
  • Post-Synaptic Density / drug effects*
  • Protein Processing, Post-Translational / drug effects
  • Receptors, AMPA / metabolism
  • Receptors, Metabotropic Glutamate / agonists
  • Tacrolimus / pharmacology
  • Tacrolimus / therapeutic use*

Substances

  • Calcineurin Inhibitors
  • Disks Large Homolog 4 Protein
  • Dlg4 protein, mouse
  • Membrane Proteins
  • Neuroprotective Agents
  • Receptors, AMPA
  • Receptors, Metabotropic Glutamate
  • Phosphoserine
  • Methoxyhydroxyphenylglycol
  • Guanylate Kinases
  • Casp3 protein, mouse
  • Caspase 3
  • glutamate receptor ionotropic, AMPA 1
  • 3,4-dihydroxyphenylglycol
  • Tacrolimus